Results 261 to 270 of about 35,228 (288)

Patient‐derived organoid model of olfactory ensheathing cell tumor

International Forum of Allergy & Rhinology
Key points We developed a culture model of a human olfactory ensheathing cell tumor. Cultured organoids resemble normal ensheathing cells. Assays suggest that this model provides a tool for studying the roles of these glial cells in the maintenance of the peripheral olfactory system.
John B. Finlay, Ralph Abi Hachem, Patrick Codd, Bradley J. Goldstein   +3 more
openaire   +2 more sources

Abstract 992: Patient-derived tumor organoids of neuroendocrine prostate cancer

Cancer Research, 2017
Abstract Background: The development of neuroendocrine prostate cancer (NEPC) is one mechanism of treatment resistance to androgen receptor (AR)-targeted therapies for a subset of patients with advanced prostate cancer. This is associated with transition from a prostate adenocarcinoma to small cell/NEPC histology, low AR signaling ...
Loredana Puca, Rohan Bareja, Reid Shaw, Wouter Karthaus, Dong Gao, Chantal Pauli, Juan Miguel Mosquera, Joanna Cyrta, Rachele Rosati, Rema Rao, Andrea Sboner, Carla Grandori, Giorgio Inghirami, Yu Chen, Mark A. Rubin, Himisha Beltran   +15 more
openaire   +1 more source

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids.

Journal of visualized experiments : JoVE, 2021
Patient-derived tumor organoids (PDOs) are expected to be a preclinical cancer model with better reproducibility of disease than traditional cell culture models. PDOs have been successfully generated from a variety of human tumors to recapitulate the architecture and function of tumor tissue accurately and efficiently.
Arisa, Higa, Nobuhiko, Takahashi, Gen, Hiyama, Hirosumi, Tamura, Hirotaka, Hoshi, Kenju, Shimomura, Shinya, Watanabe, Motoki, Takagi   +7 more
openaire   +1 more source

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Journal of Visualized Experiments
Radiation therapy (RT) is one of the mainstays of modern clinical cancer management. However, not all cancer types are equally sensitive to irradiation, often (but not always) because of differences in the ability of malignant cells to repair oxidative DNA damage as elicited by ionizing rays.
Maud, Charpentier, Norma, Bloy, Silvia C, Formenti, Lorenzo, Galluzzi, Sandra, Demaria   +4 more
openaire   +2 more sources

Evaluation of Multispecific Drugs Based on Patient‐Derived Immunocompetent Tumor Organoids

ChemBioChem
AbstractThe evolution of antitumor drug development has transitioned from single‐agent chemotherapy to targeted therapy, immunotherapy, and more recently, multispecific drugs. These innovative drugs target multiple cellular or molecular pathways simultaneously, offering a more comprehensive anticancer approach and addressing some of the limitations ...
Zihan Zhao, Xiangyu Wu, Tianyang Zhang, Meng Zhou, Siyang Liu, Rong Yang, Jie P. Li   +6 more
openaire   +2 more sources

[Patient-derived tumor organoids (or tumoroid) as valuable precision medicine tools].

Medecine sciences : M/S, 2022
Review of literature shows that it is possible to establish tumor-derived organoids, or tumoroids, from almost any type of tumor, and that these "micro-tumors" could be used to develop functional assays allowing the prediction of the patient response to treatments and/or the identification of predictive molecular signatures associated with the ...
Marion, Perréard, Romane, Florent, Lucie, Thorel, Audrey, Vincent, Louis-Bastien, Weiswald, Laurent, Poulain   +5 more
openaire   +1 more source

Expert consensus on culture of patient derived tumor organoids and organoids based drug sensitivity testing

Journal of Organoid and Bioscience
The precision treatment of cancer has consistently been a significant issue in clinical management as well as medical research. With the rapid development and advances towards clinical application of organoids technology, the use of organoids derived from both normal and cancer tissues for pathophysiology studies, treatment regimen development, and ...
Ekmu Batul, Bing Chen, Fang Chen, Liming Cheng, Shi Chen, Xueqin Chen, Kun Deng, Shigang Ding, Jiali Fan, Quansheng Gao, Jialin Gou, Kun Han, Xinyu Hao, Yuedong He, Tieying Hou, Zhanying Hong, Hui Li, Jing Li, Lin Li, Tao Li, Xiaoqin Li, Jinbo Liu, Jiyan Liu, Xin Lin, Yang Luo, Jing Peng, Mingting Peng, Chongyang Shen, Hongyu Sun, Zhibing Wu, Bing Xia, Dan Xia, Huayang Xing, Chong Xu, Li Yang, Zhenyu Yang, Zhirong Yang, Mingliang You, Xianghua Yi, Bin Zhang, Fengbo Zhang, Xiao Zhang, Maohua Zhou, Yiwen Zhou, Yi Zhou, Lijuan Wu   +45 more
openaire   +1 more source

Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites

Cancer Cell, 2023
Laura Moonen, Wenzel M Hackeng, Catherine VOEGELE   +2 more
exaly  

Tumor organoids: Opportunities and challenges to guide precision medicine

Cancer Cell, 2021
Vivien Veninga, Emile E Voest
exaly  

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions

Ca-A Cancer Journal for Clinicians, 2021
Michael L Cheng, Heather A Parsons, Atish D Choudhury   +2 more
exaly